Ciforadenant

Ciforadenant ( , ; developmental code names CPI-444 and V-81444) is an adenosine A 2A receptor antagonist which is under development for the treatment of renal cell carcinoma and non-small cell lung cancer.

Uses your system voice; voice and rate in settings.

≈ 2 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ciforadenant ( , ; developmental code names CPI-444 and V-81444) is an adenosine A 2A receptor antagonist which is under development for the treatment of renal cell carcinoma and non-small cell lung cancer. It is or was also under development for the treatment of attention-deficit hyperactivity disorder (ADHD), cancer, multiple myeloma, Parkinson's disease, and solid tumors, but no recent development has been reported for these indications.

The drug is taken orally. It shows high affinity for the adenosine A 2A receptor (K i = 3.54 nM) and high selectivity for this receptor over the other adenosine receptors (54- to 693-fold). The elimination half-life of ciforadenant is 3 hours with a single dose and 10.2 to 10.6 hours with multiple repeated doses in humans.

Ciforadenant was originated by Vernalis and is under development by Corvus Pharmaceuticals. As of January 2026, it is in phase 2 clinical trials for renal cell carcinoma and phase 1/2 trials for non-small cell lung cancer, whereas there has been no recent development for other uses.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372017592 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001372017592 · captured 2026-08-29 · ledger · version history

Cite this page as: encyclopegia.org, “Ciforadenant”, snapshot enwiki-001372017592. https://encyclopegia.org/a/ciforadenant

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.